International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

Revolutionizing Heart Failure Management: Novel Drug Therapies and Cutting-edge innovation in Heart Failure Treatment

Shruti C More*, Ms Priya S Shinde, SanikaVeer, Dipak Jaybhaye , Yash Pisal .
Yashoada Technical Campus ,Satara
Affiliated with Dr. Babasaheb Ambedkar Technology University Lonere, Raigad

Date of Submission: 15-04-2025 Date of Acceptance: 25-04-2025

ABSTRACT
Chronic heart failure is a major global cause of disease and death. While beta- blockers and ACE inhibitors have enhanced patient outcomes, many individuals remain at risk for heart failure overtime. Researchers are actively exploring new and effective treatments, driven by recent challenges in therapeutics as the pharmaceutical landscape evolves. This study explores the latest insights into heart failure (HF) pathophysiology and how emerging drugs and innovative technologies are transforming HF treatment. Additionally, we discuss potential future strategies that could dramatically enhance patient outcomes, while also addressing the limitations of existing approaches.
In recent years, therapeutic targets aimed at improving heart failure pathophysiology have been discovered, and new drugs are currently under investigation. However, it has been consistently noted that the positive findings fromphaseIIandclinicaltrialsdonotalwayscarryovert ophaseIIIstudies.This review examines ventricular remodeling, renin-angiotensin-aldosterone system activation, calcium cycling abnormalities, and other emerging treatment targets, along with their mechanisms and effectiveness.
Keywords -Heart Failure Treatment , Novel Drug Therapies, Cutting-edge Innovations, Hear tFailure Management, Pathophysiology of Heart Failure, Ventricular Remodeling, Renin- Angiotensin-Aldosterone System, Emerging Therapeutic Targets

I. INTRODUCTION

Left ventricular dysfunction leads to heart failure, which presents with symptoms like fatigue, shortness of breath, and diminished exercise capacity. With over 56 million individuals affected globally and a standardized rate of 711.90 per 10,000 people, this is a significant public health concern. Between 1% and 2% of those with heart failure (HF) experience this complex condition, which includes additional symptoms and comorbidities alongside the primary ones [1]. HF remains a critical clinical and public health challenge. Its prevalence is projected to increase as the population ages, which diminishes patients' quality of life and heightens the financial burden on individuals and the healthcare system. Heart failure is a chronic cardiovascular disorder that poses serious health risks, characterized by high prevalence, morbidity, mortality, and substantial healthcare expenditures linked to its clinical manifestations[2].

There are two main forms of heart failure: acute and chronic. Acute heart failure syndrome refers to the rapid or gradual onset of heart failure symptoms that require urgent intervention. Additionally, various comorbidities, including coronary artery disease, can worsen heart failure. Conditions such as hypertension, arrhythmia, diabetes, kidney failure, chronic obstructive pulmonary disease, and anemia should be recognized and addressed in therapeutic goals, as they not only fulfill the requirements of standard treatment but also play a role in the pathophysiology of heart failure. This review aims to highlight recent advances that significantly impact heart failure management. The discussion will be organized into several categories: device-based interventions, new pharmacological therapies, heart failure biomarkers, and emerging trends[3].

PATHOPHYSIOLOGY

Recent recurring themes highlight significant changes in the conduction and activation of the arr hythmogenic substrate, alongside the functional down regulation of potassium currents and abnormal calcium handling. These alterations affect the heart's electrical

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

functions, increasing the risk of potentially fatal cardiac arrest and prolongation of arrhythmia action potentials[15]

Why does heart failure lead to sudden cardiac death? The exact mechanism of sudden cardiac death (SCD) remains unclear in individual patients. SCD is defined by a sequence of events, with the occurrence of lethal cardiac arrhythmias—most often ventricular tachycardia or fibrillation—being the primary cause. In contrast, pulse less electrical activity is rarer and typically observed in patients with more advanced structural heart disease. Factors contributing to sudden death in heart failure patients include action potential prolongation,calciumhomeostasisdisturbances,aberrantconduction,alternative signaling pathways, and hereditary susceptibility.[4][15]

- Cardiac remodeling refers to the structural changes in the heart following an injury, such as a myocardial infarction, leading to myocyte hypertrophy and alterations in the extracellular matrix that cause either ventricular dilation or hypertrophy.[3]
- Neurohormonal Activation: Elevated levels of nor epinephrine, angiotensin II, and aldosterone occur due to the activation of both the sympathetic nervous system and the renin-angiotensin-aldosterone system. While this chronic activation initially serves a compensatory role, it ultimately leads to further cardiac remodeling and vasoconstriction coupled with sodium retention. [3]
- Higher levels of pro-inflammatory cytokines(TNF-alpha, IL-1, andIL-6) are present in heart failure, which exacerbates cardiac dysfunction and disease progression.[3]
- Calcium handling impairment: Disturbances in calcium homeostasis negatively affect cardiomyocyte excitation-contraction coupling, resulting in decreased contractility and impaired relaxation.[3]

NOVEL DRUG THE RAPIES IN HEART FAILURE TREATMENT

1. Angiotens in Receptor-Neprilys in Inhibitors (ARNIs)

Drug: Sacubitril/ Valsartan(Entresto®)

According to numerous studies, ARNI (angiotensin receptor– neprilysin inhibitor), beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors), and mineral corticoid receptor antagonists (MRA) are the mainstays of treatment for patients with HFrEF, with class1recommendations in guidelines [7] This novel drug (Sacubitril– Valsartan) demonstrated significant clinical benefit for the first time in the PARADIGM-HF trial. ARNI decreased cardiovascular mortality (13.3% vs. 16.5%; hazard ratio (HR): 0.8) and heart failure hospitalization as compared to enalapril. [2] [6]

2. Sodium-Glucose Co-Transporter-2(SGLT2) Inhibitors

Drugs: Dapagliflozin (Farxiga®), Empagliflozin (Jardiance®)

Sodium-Glucose Cotransporter 2 Inhibitors, or SGLT2. SGLT2 inhibitors help diabetics with their body weight, blood pressure, glycemia,and albuminuria. Empagliflozin significantly reduced nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes, according to EMPA-REG researchers[8] Compared to the control arm, which experienced 43.9 adverse events per 1000 patient-years (HR—0.86), the empagliflozin arm experienced 37.4 adverse events per 1000patient-years. Empagliflozin also decreased hospitalizations for heart failure and deaths altogether [2][9] Eventually, the CANVAS group then reported that can agliflozin reduced cardiovascular mortality and morbidity in 2017 [16].Similar to the EMPAREG study, the composite primary outcome happened in 26.9 participants out of 1000 patient-years in the intervention group, while the control group had 31.5 people (HR—0.86).A strong indication of fewer heart failure hospitalizations was also present, with 5.5 versus8.7 occurrences in the intervention and control arms, respectively(HR:0.67).Inindividualswithahistoryof peripheralarterydisease, high amputation rates prompted safety concerns.

The EMPEROR-Reduced and DAPA-HF investigations focused on patients with HFrEF, whether or not they had diabetes. Dapagliflozin [17] and Empagliflozin both showed significant advantages in their primary outcome, which was hospitalization for heart failure or cardiovascular death, with hazardratios of 0.74 and 0.75, respectively. [2][5]

3. GLP (Glucagon-like Peptide)-1Agonist

Glucagon-like peptide-1 and its agonist Numerous earlier studies evaluating GLP-1 receptor and cardiovascular outcomes did not include heart failure outcomes as one of their main objectives[9] In the HARMONY research,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

albiglutide (HR—0.71) reduced heart failure hospitalizations. Baseline LVEF and NYHA categorization were excluded from the trial. Focusing on HFpEF, the recent GLP-1 investigation STEP-HFpEF showed improvements in exercise function and symptoms. Even in the absence of diabetes mellitus, semaglutide was demonstrated to offer cardiovascular advantages in obese patients in a different recent trial. [2] [5]

4. Soluble Guanylate Cyclase stimulator

Vericiguat (Verquvo®)

Reactive oxygen species and endothelial dysfunction reduce the bioavailability of nitricoxidein heart failure, which leads to a relative lack of soluble guanylate cyclase [10]. Through a binding location independent of nitric oxide, vericiguat decreased cyclic GMP synthesis and directly stimulated soluble guanylate cyclase, enhancing the cyclic GMP pathway. [2]

CUTTING-EDGE INNOVATIONS IN HEART FAILURE TREATMENT

1. GENE THERAPY

A new discipline known as gene therapy is being developed to address heart failure and overcome the limitations of existing mechanical and pharmaceutical therapies. Heart failure remains a significant source of morbidity and mortality in the US, accounting for half a million deaths each year, despite substantial progress. Gene therapy is a promising alternative that targets the molecular causes of cardiacdys function. Non viral vectors exhibit low transfection efficiency, are safe, and have reduced immunogenicity. Commonly used viral vectors include adenovirus, retrovirus, Sendai virus, and adeno-associated virus (AAV). AAV vectors are particularly promising due to their low immunogenicity, sustained gene expression, and effective transduction of cardiomyocytes.[17]

AAV Vectors: AAV vectors have an excellent safety profile and are considered non-toxic. Specifically, AAV 1, AAV 6, AAV 8, and AAV 9 demonstrate high cardiac tropism. Techniques for capsid modification and directed evolution are used to enhance cardiac tropism.

Techniques for Gene Delivery:

The effectiveness of antegrade arterial infusion varies but is less invasive. Retrograde venous infusion, while complicated and effective, requires careful pressure monitoring. Aortic cross-clamping is highly effective but very invasive. Intravenous infusion is simple but only suitable for small animals due to its poor heart selectivity. Direct intramyocardial injection achieves high local concentrations but is restricted to specific areas. Pericardial injection results in limited systemic dissemination on a larger scale.

Targets for Gene Therapy:

β-Adrenergic System: Over expression of β2-AR and inhibition of GRK2 enhance cardiac function. Ca ² Cycling Proteins: Over expression of SERCA 2 a, inhibition of phospholamban, and modulation of protein phosphatase inhibitor- 1 are notable strategies. S 100 A 1 enhances cardiac contractility and relaxation function. SUMO 1 modulates SERCA 2 levels and activity. Stem Cell Homing: The SDF1/CXCR4 complex promotes stem cell homing to the infracted myocardium. Cell Death: Anti-apoptotic strategies include the use of Bcl- 2, Akt, or PI 3 kinase.

Clinical Trials:

CUPID Trial: Evaluated the safety and efficacy of AAV1. SERCA2 a gene transfer in patients with advanced heart failure, showing promising results. Ongoing Trials: Targeting SERCA2 a, adenylyl cyclase type 6,and SDF-1

2. STEMCELL AND REGENERATIVE THERAPY

The goal of stem cell and regenerative treatment for heart failure is to replace or repair damaged heart tissue to restore cardiac function. To overcome the drawbacks of traditional therapies, this strategy makes use of stem cells and associated technologies' capacity for regeneration. Crucial Points: Treatment with Stem Cells: The SDF1/CXCR4 complex is a crucial therapeutic target for encouraging stem cell homing to injured myocardium. For ischemic cardiomyopathy, this pathway is being investigated in clinical trials. Pim-1 Kinase: Promotes cardiac progenitor cells' survival, growth, and functional engraftment. Pim-1 also supports myocardial regeneration and lineage commitment."

Mechanisms of Action.

Cardiomyocytes or other cardiac cell types can be produced from stem cells. They release paracrine substances that suppress apoptosis, lower inflammation, and encourage angiogenesis. Additionally, stem cells can enhance the injured heart's microenvironment and regulate the immune response. [17-20]

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

Stem cell types that are utilized include:

Unique to the heart, cardiac progenitor cells can differentiate into cardiomyocytes. Bone marrow and adipose tissue contain mesenchymal stem cells (MSCs), which have regenerative and immunomodulatory qualities. Reprogrammed adult cells, induced pluripotent stem cells (iPSCs), can differentiate into any type of cell, including cardiomyocytes. Pluripotent cells with significant regeneration potential and embryonic stem cells (ESCs) raise ethical and immunological questions. [11]

Challenges

Engraftment and Survival: Transplanted cells have poor survival rates in the harsh environment of the injured heart. Arrhythmogenic Risk: The possibility that abnormal cardiacrhythms could result from in correct new cell integration. The risk of an immunological reaction against transplanted cells, particularly when they come from all ogeneicorigins, is known as immune rejection. Scalability and Standardization: Producing large amounts of high-quality stem cells for clinical usage is difficult. [9]

Clinical Trials:

Ongoing trials are investigating the safety and efficacy of stem cell therapies for heart failure, including direct injection of stem cells into the myocardium and systemic delivery.

FUTURE DIRECTIONS FOR STEM CELL THERAPHY

The goal of future research is to improve stem cell therapy for the treatment of heart failure. Developments in IPSC technology allow for customized approaches to heart regeneration and disease modeling. Stem cells, biomaterials, and tissue engineering methods can be used to create functioning cardiac constructions or patches. Investigating synergies with growth factors, gene therapy, or pharmaceutical drugs may also improve results and increase regenerative benefits. In conclusion, cutting-edge strategies to tackle the intricate problems of treating heart failure include regenerative medicine and stem cell therapy. Current barriers are being addressed by ongoing research projects, which will open the door to more individualized and efficient treatments.

NANOPARTICLE-BASED CARDIAC-SPECIFIC DRUGDELIVERY

A broad range of cardiovascular disorders, including atherosclerosis, thrombosis, myocardial infarction, and heart failure, can be treated with nanoparticles. They can be used in a variety of therapeutic techniques, such as gene therapy, targeted medication delivery, and theranostic procedures that combine diagnosis and treatment. Each of the following nanoparticle types—liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles—has special qualities that make them appropriate for particular cardiovascular applications. It is possible to design these nanoparticles to target particular heart system components. By fine-tuning their surface properties and in corporating specific ligands, researchers can enhance the effectiveness of these nanoparticles in targeting damaged tissues or delivering drugs precisely where they are needed most. This innovative approach could lead to significant advancements in cardiovascular medicine, ultimately improving patient outcomes and reducing the burden of heart-related diseases [20].

LIPOSOMES

Particularly for the treatment of CVDs, liposomes are among the oldest and best-studied nanoparticle systems for drug delivery. Both hydrophilic and hydrophobic medications can be encapsulated in these spherical vesicles, which are composed of phospholipid bilayers, enhancing drug stability and bioavailability. When altered using polyethylene glycol (PEG) to create "stealth" liposomes, their structure resembles that of natural cellular membranes, offering exceptional biocompatibility. They also avoid the immune system, prolonging their circulation time.[25]

MECHANISM OF ACTION

Effective intracellular medication administration is made possible by liposomes' capacity to fuse with cell membranes; this property is significant for cardiovascular applications. PEGylation improves their drug transport efficacy and stealth qualities by delaying the reticuloendothelial system's quick clearance. Many cardiovascular treatments now have higher bioavailability thanks in large part to this technique.[26]

II. POLYMERICNANOP ARTICLES

In the field of nanomedicine, polymeric nanoparticles (PNPs) have attracted a lot of interest because of their adaptable characteristics and potential for effective body absorption [28]. A wide range of systems, including solid nanoparticles,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

amphiphilic nanoparticles, dendrimers, and star-shaped structures, are included in the category of polymeric nanoparticles; each has distinct architectural traits and attributes [29]. Numerous nonbiodegradable polymers, such as polymethylmethacrylate (PMMA), poly(acrylamide), poly(styrene),and poly(acrylates), have been extensively researched for a range of uses; however, these materials have been linked to chronic toxicity over time, which has caused attention to shift toward biodegradable alternatives [30].

Polylactic acid (PLA), polyglycolic acid (PGA), and poly-lactic-co- glycolic acid (PLGA) are the most often utilized polymers for biodegradable nanocarriers. These substances can naturally decompose into carbon dioxide and water, which makes them biodegradable and suitable for drug administration. The most researched of these for the treatment of cardiovascular disease is PLGA because of its efficient drug release and biocompatibility [35].

MECHANISM OF ACTION

PNPs can adsorb pharmaceuticals onto their surface or encapsulate them within their core, making them a flexible drug delivery platform. These nanoparticles can be designed to release drugs in a regulated manner using processes like diffusion, erosion, and stimuli-responsive systems (including pH, temperature, and light). To improve the accuracy of drug administration, stimuli-responsive PNPs can release medications in response to particular internal or external triggers [31-32]. Enhancing site- specific drug delivery in particular cardiovascular tissues and types by functionalizing PNPs with targeting ligands(such as enzymes, antibodies, or peptides) can improve therapeutic outcomes and minimize side effects[33].

III. DENDRIMERS BASED THERAPIES

Dendrimers are extremely branching, tree-like polymers that provide a distinct structure with several surface functional groups, which makes them perfect for targeted delivery and drug conjugation. A high drug- loading capacity, multi functionality, and exact control over their size, shape, and surface characteristics are only a few benefits of their construction. These characteristics make dendrimers particularly successful in various therapeutic applications, such as the treatment of cancer and cardiovascular disease, by improving the solubility and bioavailability of medications[36]

MECHANISM OF ACTION

Drugs can be transported by dendrimers either by conjugating them to their many surface groups with specific ligands or antibodies for active targeting or by encasing them within their interior cavities. Their well- defined size and shape help to provide predictable and consistent pharmacokinetic profiles, and their highly branching structure enables a high drug-loading capacity. Dendrimers are also excellent candidates for theranostic applications, which combine therapy and diagnostics on a single platform, because their multivalent surface can be functionalized with targeted ligands or imaging agents. Of the many dendrimers utilized for drug administration, the polyamidoamine (PAMAM) dendrimer is the one that is chosen the most frequently [41-34]

IV. IN ORGANIC NANO PARTICLES

A broad class of nanomaterials with distinct physicochemical characteristics, inorganic nanoparticles are ideal for biological uses, such as the management of cardiovascular diseases. These nanoparticles are oftendividedintometallic,non-metallic,carbon-basednanomaterials,and quantum dots according to their composition; each has unique characteristics that make it useful for certain medical therapeutic and diagnostic applications[38-39]

MECHANISM OF ACTION

Gold, iron oxide, and silica nanoparticles are examples of inorganic nanoparticles that have unique optical, magnetic, and thermal properties that make them ideal for various cardiovascular medical applications. These characteristics could be utilized. Their surfaces are readily functionalized with therapeutic compounds or targeting ligands in drug delivery, allowing for the tailored delivery of medications to sick tissues with the least amount of systemic exposure[40].

V. CHALLENGES AND FUTURE DIRECTIONS

A number of obstacles stand in the way of the clinical application of nanoparticle-based treatments in cardiovascular health, despite encouraging preclinical findings. Potential long-term toxicity, accumulation in non-target organs, and the requirement for thorough assessments of their bio distribution and clearance are some of the common problems that inorganic nanoparticles

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

encounter [38-40]. Clinical adoptionofdendrimer-basedtherapeuticsiscomplicatedbyissuessuchas lack of biodegradability, expensive manufacturing, and cytotoxicity at higher doses [41]. In order to address worries about toxicity from degradation, polymeric nanoparticles need to have their drug loading, release kinetics, and stability further optimized [28-29]. In addition to the difficulty in precisely targeting liposomes in cardiovascular tissues, liposomes pose issues with scalable production, stability during storage, and the potential for immunological reactions with repeated treatment.

Ensuring biocompatibility is one of the biological issues since long-term safety profiles are frequently ambiguous, which raises questions regarding immunological reactions and accumulation in non-target organs. Because the size, shape, and surface characteristics of nanoparticles greatly affect how they behave in vivo, it is imperative to optimize bio distribution and clearance. Despite encouraging in vitro results, achieving effective targeting in the intricate cardiovascular milieu is still a challenge.

Technological problems include improving drug release kinetics, preserving formulation stability during storage, and scaling up production to satisfy GMP standards. Because nanoparticle-based treatments are frequently categorized as combination products, which leads to uncertainty in the approval processes, regulatory frameworks continue to be a major obstacle. To overcome these obstacles, cooperation is needed to create rules that take into account the special characteristics of nanoparticles [45-46-47].

VI. CONCLUSION

The treatment of cardiovascular illness could be revolutionized by nanoparticle-based medicines because they improve medication delivery, reduce side effects, and improve therapeutic outcomes. Platforms that provide flexible answers for the intricacies of cardiovascular therapy include liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles. Better targeting and innovative treatments are demonstrated by preclinical research, but implementing these developments in clinical practice is fraught with difficulties, such as biocompatibility, scalable manufacturing, and regulatory barriers. Creating multifunctional nanoparticles that can deliver combination medicines, integrate diagnostics with therapy, and adjust to the cardiovascular environment is the way of the future.

More treatments will probably make it to clinical trials as our knowledge of nanoparticle interactions and manufacturing processes develops. Continued cooperation between researchers, physicians, and regulatory agencies will be necessary for success. With careful work, treatments based on nanoparticles may greatly improve the treatment of cardiovascular conditions, improving patient outcomes in this crucial area

CHALLENGES AND FUTURE DIRECTIONS

The most encouraging results for near-future developments are given by gliflozins. Encouraging results in type 2 diabetic patients with prior CV events from the EMPAREG-HF study (empagliflozin), from the CANVAS program (can agliflozin), and from the DECLARE-TIMI 58 trial (dapagliflozin)induced researchers to test SGLT2i in people with HF regardless of the presence of diabetes mellitus. Results from the DAPA- HF trial and the EMPEROR-Reduced trial in both diabetics and non- diabetics showed an important reduction in CV death and HF hospitalization. The mechanisms underlying the cardiac effects of gliflozins have not yet been fully defined, although possible effects of these drugs on cardiomyocytes couldbe supposed. Ongoing clinical trials will clarify the effects and mechanisms of gliflozins in HFrEF and HFpEF patients with and without T2DM. New results havebeen derived from the studies on end othelial function in CHF; especially interesting results have been obtained in HFpEF in treatment with empagliflozin. Other possible approaches for the future include RyR2 and its associated accessory proteins, which might be potential new drug targets. RyR2 placed on the sarcoplasmic reticulum produces systolic Ca^{2+} transients within cardiomyocytes. Appropriate functioning of RyR2 is therefore pivotal to the timing and force produced by cardiomyocytes. Impaired intracellular Ca^{2+} handling secondary to impaired function of RyR2 may be related to HF.NormalcardiacCa^{2+} handling is also due to striated muscle preferably expressing protein kinase (SPEG), a member of the myosin light chain kinase family. SPEG has been causally linked to HF and a trial fibrillation, so it can be taken into consideration. Gene therapy is still far from being clinically applicable. The gene cysteine-rich secretory protein LCCL domain containing 1 (CRISPLD1) is over expressed in HF. The down regulation of some signaling pathways upon CRISPLD1-KO implicates a role in adverse

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1887-1895 www.ijprajournal.com ISSN: 2456-4494

remodeling. These discoveries offer novel candidate genes with encouraging potential roles for therapeutic intervention. The cardiac bridging integrator 1 gene (cBIN1) therapy stabilizes the subcellular membrane within cardiomyocytes. Preserving the intracellular distribution of calcium potentially could be a new way forward to finding new drugs[20].

Gene therapy has yet to be used in clinical settings. The over expression of the gene cysteine-rich secretory protein LCCL domain-containing 1 (CRISPLD1) is observed in heart failure. Certain signaling pathways are down regulated by CRISPLD1-KO, which suggests an involvement in unfavorable remodeling. These findings present new candidate genes with promising potential use in therapeutic approaches. By maintaining the intracellular calcium distribution and stabilizing the sub cellular membrane within cardiomyocytes, cardiac bridging integrator 1 gene (cBIN1) therapy may pave the way for the development of novel medications[17].

CONCLUSION

Heart failure continues to be a serious health problem despite advancements in medicine, leading to high morbidity and medical costs. Promising outcomes have lately been observed from ongoing efforts to improve medical care aimed at these high-risk groups. Heart failure with maintained ejection fraction is still difficult to treat because there aren't many evidence-based treatment alternatives. Reducing the global illness burden may be achieved by implementing early, suitable risk factor adjustments and using artificial intelligence to identify at- risk groups. The next significant advancement in the treatment of heart failure will be gene therapy using cutting-edge gene-editing technologies.

ACKNOWLEDGEMENT

I have to say thanks to my guide Ms. Priya S Shinde for her constructive suggestions, meticulous support and constant motivation. Appreciation is also extended to “YSPM, Yashoda Technical Campus Faculty Of Pharmacy, Wadhe Satara” for providing the necessary resources and support during the preparation of this manuscript. Finally, we thank all the researchers whos evaluable work has been cited and discussed in the article.

REFERENCES

[1]. Tamargo J, López-Sendón J. Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov. 2011 Jul;10(7):536–555.

[2]. Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, et al. Burden, trends, and in equalities of heart failure globally,1990to2019:a secondary analys is based on the Global Burden of Disease 2019 Study. J Am Heart Assoc. 2023;12(4):e027852. doi:10.1161/JAHA.122.027852

[3]. Devadoss R, Dhillon G, Sharma P, Verma RK, Munjal R, Kashyap R. Heartfelt breakthroughs: Elevating quality of life with cutting-edge advances in heart failure treatment. J Cardiovasc Dev Dis. 2024;11(1):15. doi:10.3390/jcdd11010015

[4]. McMurray JJV, Pfeffer MA. Clinical trials in heart failure: are there any lessons to be learned? Part I. Circulation. 2002 Apr 30;105(17):2099–2106.

[5]. Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M, Brunetti ND. New targets in heart failure drug therapy. Front Cardiovasc Med. 2021;8:665797. doi:10.3389/fcvm.2021.665797

[6]. GhionzoliN, GentileF, Del Franco AM, Castiglione V, Aimo A, Giannoni A, et al. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2021. doi:10.1007/s10741-021-10134-7

[7]. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. doi:10.1093/eurheartj/ehw128

[8]. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–48. doi:10.1056/NEJMoa1812851

[9]. SolomonSD, McMurrayJJV,AnandIS, GeJ,LamCSP, MaggioniAP, etal. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. NEnglJMed.2019; 381(17):1609–

20. doi:10.1056/NEJMoa1908655
[10]. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin–neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;82(1):1–12. doi:10.1016/j.jacc.2023.04.02
[11]. NealB, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, etal. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. doi:10.1056/NEJMoa1611925
[12]. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15):1413–24. doi:10.1056/NEJMoa2022190
[13]. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the angiotensin- receptor neprilysin inhibitor on cardiac reverse remodeling: a meta-analysis. Circulation. 2025 Apr 4. Available from: http://ahajournals.org
[14]. Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2020;10(5):1465–1483. doi:10.21037/cdt-20-30
[15]. Piano MR, Bondmass M, Schwertz DW. The molecular and cellular pathophysiology of heart failure. Heart Lung. 1998 Jan-Feb;27(1):3–19; quiz 20–1. doi:10.1016/s0147-9563(98)90063-2
[16]. Hajjar RJ. [Title of the article]. Circ Res. 2012; [volume(issue)]:[page numbers]. Available from: http://circres.ahajournals.org
[17]. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013 Sep 21;34(36):2795–2807. doi: 10.1093/eurheartj/eht192.
[18]. Segers V, Lee R. Stem-cell therapy for cardiac disease. Nature. 2008 Feb 21;451(7181):937-42. doi:10.1038/nature06800.
[19]. Jha G, Sharma RB, Sridhar S, Kurrey NK, Arora A, Sharma S, et al. Nanoparticle-based therapies for cardiovascular diseases: a literature review of recent advances and clinical potential. Cureus.2024Oct31;16(10):e72808. doi:10.7759/cureus.72808.
[20]. Tang J, Lobatto ME, Read JC, Mieszawska AJ, Fayad ZA, Mulder WJ. Nanomedical theranostics in cardiovascular disease. Curr Cardiovasc Imaging Rep. 2012;5(1):19–25. doi:10.1007/s12410-011-9120-6
[21]. Maleki Dizaj S, RadAA, Safaei N, Salatin S. The application of nanomaterials in cardiovascular diseases: a review on drugs and devices. J Pharm Pharm Sci. 2019; 22(1):501–15. doi:10.18433/ jpps3045
[22]. Akram Z, Raza A, MehdiM, Arshad A, Deng X, Sun S. Recent advancements in metal and non-metal mixed-doped carbon quantum dots: synthesis and emerging potential applications. Nanomaterials (Basel). 2023;13(16):2336. doi:10.3390/nano13162336
[23]. Altammar KA. A review on nanoparticles: characteristics, synthesis, applications, and challenges. Front Microbiol. 2023;14:1155622. doi:10.3389/fmicb.2023.1155622
[24]. Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics. 2022;14(3):543. doi:10.3390/pharmaceutics14030543
[25]. Ahmad MZ, Bhatnagar D, Ladhe S, et al. Liposomes and niosomes for targeted drug and gene delivery systems. In: Barabadi H, Mostafavi E, Saravanan M, editors. Pharmaceutical Nanobiotechnology for Targeted Therapy. Cham: Springer; 2022. p. 337–59. doi:10.1007/978-3-031-12658-1_12
[26]. AndraVV, PammiSV, BhatrajuLV, Ruddaraju LK. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience. 2022;12:274–91. doi:10.1007/s12668-022- 00941-x
[27]. Jiang W, Rutherford D, Vuong T, Liu H. Nanomaterials for treating cardiovascular diseases: a review. Bioact Mater. 2017;2(4):185–98. doi:10.1016/j.bioactmat.2017.11.002
[28]. Hoskins C, Thoo-LinPK,ChengWP.A review on comb-shaped amphiphilic polymers for hydrophobic drug

solubilization. Ther Deliv. 2012;3(1):59–79. doi:10.4155/tde.11.130

[29]. Banik BL, Fattahi P, Brown JL. Polymeric nanoparticles: the future of nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(2):271–99. doi:10.1002/wnan.1364

[30]. UlbrichK, Holá K, Šubr V, Bakandritsos A, TučekJ, Zbořil R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116(9):5338–431. doi:10.1021/acs.chemrev.5b00589

[31]. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dualand multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials.2013;34(14):3647–57. doi:10.1016/j.biomaterials.2013.01.084

[32]. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–27. doi:10.1038/nrd4333

[33]. Yang F, Xue J, Wang G, Diao Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Front Pharmacol. 2022;13:999404. doi:10.3389/fphar.2022.999404

[34]. Katsuki S, Matoba T, Koga J, Nakano K, Egashira K. Anti-inflammatory nanomedicine for cardiovascular disease. Front Cardiovasc Med. 2017;4:87. doi:10.3389/fcvm.2017.00087

[35]. Palmerston Mendes L, Pan J, Torchilin VP: Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017, 22:1401. 10.3390/molecules22091401

[36]. Chandarana M, Curtis A, Hoskins C. The use of nanotechnology in cardiovascular disease. Appl Nanosci. 2018;8:1607–19. doi:10.1007/s13204- 018-0856

[37]. Skourtis D, Stavroulaki D, Athanasiou V, Fragouli PG, Iatrou H. Nanostructured polymeric, liposomal and other materials to control the drug delivery for cardiovascular diseases. Pharmaceutics. 2020;12(12):1160. doi:10.3390/pharmaceutics12121160

[38]. Natarajan S, Harini K, Gajula GP, et al. Multifunctional magnetic iron oxide nanoparticles: diverse synthetic approaches, surface modifications, cytotoxicity towards biomedical and industrial applications. BMC Mater. 2019;1:2. doi:10.1186/s42833-019-0002-6

[39]. Estelrich J, Escribano E, Queralt J, Busquets MA.I ron oxide nanoparticles for magnetically-guided and magnetically-responsive drug delivery.IntJMolSci. 2015;16(4):8070–101. doi:10.3390/ijms16048070

[40]. Deng C, Sun Z, Tong G, et al.: α-Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PLoS One. 2013, 8:e58371. 10.1371/journal.pone.0058371

[41]. ScafaUdriște A, Burdușel AC, Niculescu AG, Rădulescu M, Grumezescu AM. Metal-based nanoparticles for cardiovascular diseases. Int J Mol Sci. 2024;25(2):1001. doi:10.3390/ijms25021001

[42]. Wicki A, Ritschard R, Loesch U, Deuster S, Rochlitz C, Marmot C. Large- scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR immunoliposomes for a first-in- man clinical trial. Int J Pharm. 2015;484(1–2):8–15. doi:10.1016/j.ijpharm.2015.02.034

[43]. Webb C, Forbes N, Roces CB, et al. Using micro fluidics for scalable manufacturing of nanomedicines from bench to GMP: a case study using protein-loaded liposomes. Int J Pharm. 2020;582:119266. doi:10.1016/j.ijpharm.2020.119266

[44]. Desai N. Challenges in the development of nanoparticle-based therapeutics.

[45]. AAPSJ.2012;14(2):282–95.doi:10.1208/s12248-012-9339-4

[46]. Saini R, Saini S, Sharma S. Nanotechnology: the future medicine. J Cutan Aesthet Surg. 2010;3(1):32–3. doi:10.4103/0974-2077.63301

[47]. Đorđević S, Gonzalez MM, Conejos-Sánchez I, et al. Current hurdles to the translation of nanomedicines from the bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-25.doi:10.